Stealthyx's Prothyx platform confers stability and latency characteristics to therapeutic proteins and peptides.

Latest News (February 2008): Eden Biodesign and Stealthyx Therapeutics Ltd sign deal to develop enhanced treatment for rheumatoid arthiritis.

Stealthyx Therapeutics Ltd patented Prothyx technology platform is a novel approach to disease specific delivery of therapeutic molecules. The technology delivers improved clinical benefits by increasing the therapeutic window where drugs can be used safely, and broadens the re-administration interval for drugs that are administered at regular intervals. This has been demonstrated in vitro and in vivo with both proteins and peptides and has the potential to benefit other molecules including siRNA and small molecules.

Stealthyx has two partnering agreements in place. One with Cancer Research Technology to develop tumour targeted therapies (More information is available on on the Cancer Research Technology website) and the other with Biogenesis Bago for specific veterinary applications.

Stealthyx is happy to discuss further partnering opportunities for this novel platform Prothyx ® and to discuss investment opportunities in the company to develop its in-house programmes.